13F filing recap · Q4 2024

What did Engaged Capital buy in Q4 2024?

Reported stock-position changes between this filing and the previous one.

Stock value

$486.37M

Positions

Estimated turnover

31.8%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Quarter in review

Engaged Capital opened a new position in Chart Industries and exited Blackline and Nevro Corp. It trimmed Ncr Voyix Corporation and Ncr Atleos Corporation, while substantially adding to Evolent Health and substantially reducing Pra Group.

New positions

GTLSChart Industries, Inc.$42.90Mreported value+224.8K shares

Increased positions

EVHEvolent Health, Inc.$60.80Mreported value+1.42M shares+35.5%

Reduced positions

VYXNcr Voyix Corporation$79.87Mreported value-1.40M shares-19.5%NATLNcr Atleos Corporation$74.83Mreported value-802.2K shares-26.7%PRAAPra Group, Inc$12.95Mreported value-1.08M shares-63.6%

Exited positions

BLBlackline, Inc.$33.62Mprior reported value-609.7K shares-100.0%NVRONevro Corp$13.66Mprior reported value-2.44M shares-100.0%